Answers are grounded in this paper and cite their sources.
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).
No takes yet. Share an insight, caveat, or question.
Zinman et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: